We sincerely appreciate the thoughtful comments and constructive feedback from Bilgin et al. [1] regarding our study on the prognostic significance of sex-specific alanine aminotransferase (ALT) thresholds in chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) therapy [2]. The robust design of our large-scale, dual-cohort study and the application of the latent class mixed modelling to characterise longitudinal ALT trajectories have been duly recognised.